Literature DB >> 16380996

Influence of target gene mutations on survival, stage and histology in sporadic microsatellite unstable colon cancers.

Barbara Jung1, E Julieta Smith, Ryan T Doctolero, Pascal Gervaz, Julio C Alonso, Katsumi Miyai, Temitope Keku, Robert S Sandler, John M Carethers.   

Abstract

High-frequency microsatellite unstable (MSI-H) colon tumors develop as a consequence of mutations at repetitive sequences in target genes. TGFBR2 and ACVR2, encoding TGFbeta superfamily receptors, and the proapoptotic gene BAX are frequent targets for frameshift mutation. We analyzed the effect of these mutations on survival and histology in 2 separate cohorts. Forty-eight MSI-H Dukes B2 colon tumors from a cohort of 172 patients had mutations in TGFBR2, BAX and ACVR2 correlated with patient survival. Further, 54 population-based MSI-H colon cancers of all stages from a cohort of 503 patients had mutations correlated with tumor stage, grade and size. Of 44 amplifiable MSI-H Dukes B2 tumors, 70% harbored TGFBR2, 63% BAX and only 4.5% ACVR2 mutations. While mutation alone did not influence survival, concomitant mutation of TGFBR2 and BAX was associated with an improved prognosis in Dukes B2 patients (p=0.05). ACVR2 mutations were more frequent in the second, population-based cohort (stage II: 32.5%, p<0.05). While no target gene mutation correlated with stage in this cohort, poor histological grade and large tumor volume were associated with mutant ACVR2, but not TGFBR2 or BAX mutations, and likely accounts for the lower prevalence of ACVR2 mutations in the first, well-differentiated Dukes B2 cohort. Because target gene mutations did not correlate with stage, they likely occur early in the pathogenesis of MSI-H cancers. Mutations in TGFBR2 and BAX may improve survival in MSI-H Dukes B2 patients, and mutations of ACVR2 may augment histological changes consistent with poor tumor grade that is characteristic of MSI-H colon cancers, and increase tumor size. Copyright (c) 2005 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16380996      PMCID: PMC4155491          DOI: 10.1002/ijc.21710

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  22 in total

1.  Role of BAX in the apoptotic response to anticancer agents.

Authors:  L Zhang; J Yu; B H Park; K W Kinzler; B Vogelstein
Journal:  Science       Date:  2000-11-03       Impact factor: 47.728

2.  Tumor microsatellite instability and clinical outcome in young patients with colorectal cancer.

Authors:  R Gryfe; H Kim; E T Hsieh; M D Aronson; E J Holowaty; S B Bull; M Redston; S Gallinger
Journal:  N Engl J Med       Date:  2000-01-13       Impact factor: 91.245

3.  Molecular predictors of survival after adjuvant chemotherapy for colon cancer.

Authors:  T Watanabe; T T Wu; P J Catalano; T Ueki; R Satriano; D G Haller; A B Benson; S R Hamilton
Journal:  N Engl J Med       Date:  2001-04-19       Impact factor: 91.245

4.  Prognostic significance of allelic lost at chromosome 18q21 for stage II colorectal cancer.

Authors:  J M Carethers; M T Hawn; J K Greenson; C L Hitchcock; C R Boland
Journal:  Gastroenterology       Date:  1998-06       Impact factor: 22.682

5.  Diet, lifestyle, and genomic instability in the North Carolina Colon Cancer Study.

Authors:  Jessie A Satia; Temitope Keku; Joseph A Galanko; Christopher Martin; Ryan T Doctolero; Akihiro Tajima; Robert S Sandler; John M Carethers
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2005-02       Impact factor: 4.254

6.  Mutational inactivation of the proapoptotic gene BAX confers selective advantage during tumor clonal evolution.

Authors:  Y Ionov; H Yamamoto; S Krajewski; J C Reed; M Perucho
Journal:  Proc Natl Acad Sci U S A       Date:  2000-09-26       Impact factor: 11.205

7.  Prognostic implications of BAX and TGFBRII mutations in colon cancers with microsatellite instability.

Authors:  Wade S Samowitz; Karen Curtin; Susan Neuhausen; Donna Schaffer; Martha L Slattery
Journal:  Genes Chromosomes Cancer       Date:  2002-12       Impact factor: 5.006

8.  Instabilotyping: comprehensive identification of frameshift mutations caused by coding region microsatellite instability.

Authors:  Y Mori; J Yin; A Rashid; B A Leggett; J Young; L Simms; P M Kuehl; P Langenberg; S J Meltzer; O C Stine
Journal:  Cancer Res       Date:  2001-08-15       Impact factor: 12.701

Review 9.  A National Cancer Institute Workshop on Microsatellite Instability for cancer detection and familial predisposition: development of international criteria for the determination of microsatellite instability in colorectal cancer.

Authors:  C R Boland; S N Thibodeau; S R Hamilton; D Sidransky; J R Eshleman; R W Burt; S J Meltzer; M A Rodriguez-Bigas; R Fodde; G N Ranzani; S Srivastava
Journal:  Cancer Res       Date:  1998-11-15       Impact factor: 12.701

10.  Mutation of the type II transforming growth factor-beta receptor is coincident with the transformation of human colon adenomas to malignant carcinomas.

Authors:  W M Grady; A Rajput; L Myeroff; D F Liu; K Kwon; J Willis; S Markowitz
Journal:  Cancer Res       Date:  1998-07-15       Impact factor: 12.701

View more
  30 in total

1.  Both microsatellite length and sequence context determine frameshift mutation rates in defective DNA mismatch repair.

Authors:  Heekyung Chung; Claudia G Lopez; Joy Holmstrom; Dennis J Young; Jenny F Lai; Deena Ream-Robinson; John M Carethers
Journal:  Hum Mol Genet       Date:  2010-04-23       Impact factor: 6.150

2.  Flanking nucleotide specificity for DNA mismatch repair-deficient frameshifts within activin receptor 2 (ACVR2).

Authors:  Heekyung Chung; Joy Chaudhry; Jenny F Lai; Dennis J Young; John M Carethers
Journal:  Mutat Res       Date:  2011-10-05       Impact factor: 2.433

3.  Expression of GIV/Girdin, a metastasis-related protein, predicts patient survival in colon cancer.

Authors:  Mikel Garcia-Marcos; Barbara H Jung; Jason Ear; Betty Cabrera; John M Carethers; Pradipta Ghosh
Journal:  FASEB J       Date:  2010-10-25       Impact factor: 5.191

4.  Activin type 2 receptor restoration in MSI-H colon cancer suppresses growth and enhances migration with activin.

Authors:  Barbara H Jung; Stayce E Beck; Jennifer Cabral; Eddy Chau; Betty L Cabrera; Antonio Fiorino; E Julieta Smith; Melanie Bocanegra; John M Carethers
Journal:  Gastroenterology       Date:  2006-11-16       Impact factor: 22.682

Review 5.  Molecular classification and correlates in colorectal cancer.

Authors:  Shuji Ogino; Ajay Goel
Journal:  J Mol Diagn       Date:  2007-12-28       Impact factor: 5.568

Review 6.  Molecular and prognostic heterogeneity of microsatellite-unstable colorectal cancer.

Authors:  Jung Ho Kim; Gyeong Hoon Kang
Journal:  World J Gastroenterol       Date:  2014-04-21       Impact factor: 5.742

Review 7.  Transforming Growth Factor β Superfamily Signaling in Development of Colorectal Cancer.

Authors:  Barbara Jung; Jonas J Staudacher; Daniel Beauchamp
Journal:  Gastroenterology       Date:  2016-10-20       Impact factor: 22.682

8.  Secondary Prevention of Colorectal Cancer: Is There an Optimal Follow-up for Patients with Colorectal Cancer?

Authors:  John M Carethers
Journal:  Curr Colorectal Cancer Rep       Date:  2010-01-13

9.  TGFbeta modulates PTEN expression independently of SMAD signaling for growth proliferation in colon cancer cells.

Authors:  Jimmy Y C Chow; Jennifer A Cabral; Jessica Chang; John M Carethers
Journal:  Cancer Biol Ther       Date:  2008-10-22       Impact factor: 4.742

10.  Activin signaling in microsatellite stable colon cancers is disrupted by a combination of genetic and epigenetic mechanisms.

Authors:  Barbara Jung; Jessica Gomez; Eddy Chau; Jennifer Cabral; Jeffrey K Lee; Aimee Anselm; Przemyslaw Slowik; Deena Ream-Robinson; Karen Messer; Judith Sporn; Sung K Shin; C Richard Boland; Ajay Goel; John M Carethers
Journal:  PLoS One       Date:  2009-12-14       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.